Clinico-pathologic and immunophenotypic features of the whole cohort and a comparison between CLDN18-positive (≥1% of tumour cells) and CLDN18-negative SBAs (<1%) are summarized in Table 1. The gene discussed is CLDN18; the disease is neoplasm.